European Medicines Agency Recommends Ronapreve, Regkirona Covid-19 Treatments for Approval
November 11 2021 - 11:43AM
Dow Jones News
By Olivia Bugault
The European Medicines Agency on Thursday recommended the
authorization of the Ronapreve and Regkirona monoclonal antibody
drugs for the treatment of Covid-19.
The agency's recommendation for Ronapreve is for people over 12
years old and weighing at least 40 kilos who don't need
supplemental oxygen and that have higher risks of developing severe
symptoms, it said. The recommendation is for the treatment of the
disease or its prevention, the EMA said. Ronapreve is jointly
developed by Swiss pharma Roche Holding AG and the U.S.'s Regeneron
Pharmaceuticals Inc.
Regkirona, developed by South Korean biopharma company Celtrion,
is recommended for approval for adults also not requiring extra
oxygen and whose disease is more likely to become more severe, it
said.
The agency will "now send its recommendations for both medicines
to the European Commission for rapid legally binding decisions," it
said.
Write to Olivia Bugault at olivia.bugault@wsj.com
(END) Dow Jones Newswires
November 11, 2021 11:28 ET (16:28 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
